Litcius/Paper detail

120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study

James Chih‐Hsin Yang, Alexander Luft, Emmanuel de la Mora Jimenez, Jun S. Lee, P. Koralewski, Nuri Karadurmuş, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin, Julia Dudnik, Daisy Ortiz, Tarek Mekhail, Chinyere E. Okpara, Zachary Zimmer, Ayman Samkari, Niyati Bhagwati, Tibor Csőszi

2021Annals of Oncology20 citationsDOI

Topics & Concepts

MedicinePembrolizumabInternal medicineFirst line treatmentOncologyFirst linePopulationPlaceboTolerabilityStock optionsPhases of clinical researchMetastatic melanomaClinical trialAdverse effectCancerChemotherapyImmunotherapyPathologyEnvironmental healthAlternative medicineFinanceEconomicsCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study | Litcius